New Study on Liraglutide Market | Analysis by Key Players, Types and Regions to 2025

This report studies the global Liraglutide market status and forecast, categorizes the global Liraglutide market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, India, Southeast Asia and other regions (Central & South America, and Middle East & Africa).

Marketed under the brand name Victoza, Liraglutide (NN2211), is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. under the brand name Saxenda as a treatment for obesity in adults with at least one weight-related comorbid condition.
The total amount of Patents about Liraglutide are 1871, among those Patents, 44% is about application, 26% is about Combination therapy, and 12% is about Preparation method.
In these patents, accounting for Europe is the largest, followed by North America, and finally Asia.
The application of Liraglutide
Liraglutide for the treatment of type 2 diabetes mellitus
Liraglutide 1.2 mg daily in triple therapy regimens (in combination with metformin and a sulphonylurea, or metformin and a thiazolidinedione) is recommended as an option for the treatment of people with type 2 diabetes, only if used as described for exenatide in 'Type 2 diabetes: the management of type 2 diabetes
Liraglutide 1.2 mg daily in dual therapy regimens (in combination with metformin or a sulphonylurea) is recommended as an option for the treatment of people with type 2 diabetes, only if the person is intolerant of either metformin or a sulphonylurea, or treatment with metformin or a sulphonylurea is contraindicated, and the person is intolerant of thiazolidinediones and dipeptidyl peptidase-4 (DPP-4) inhibitors, or treatment with thiazolidinediones and DPP-4 inhibitors is contraindicated.
The Committee concluded that people with type 2 diabetes currently receiving liraglutide who do not meet the criteria specified in section 1.1 or 1.3, or who are receiving liraglutide 1.8 mg, should have the option to continue their current treatment until they and their clinicians consider it appropriate to stop.

Ask for Sample copy of this report at https://www.inforgrowth.com/samplerequest/global-liraglutide-market-professional-survey-report-2018.

The following manufacturers are covered in this report: HEC Pharm, Bachem, Bharat Pharmaceuticals, Kingpep Biotechnology, Shenzhen JYMed Technology, Wuxi Asiapeptide, AmbioPharm.

Liraglutide Breakdown Data by Type: Pills, Liquid.

Liraglutide Production by Region: North America, Europe, China, Japan, India, Southeast Asia, Other regions (Central & South America, Middle East & Africa).

Liraglutide Breakdown by the customized separate regional or country-level reports, for the following regions: North America, United States, Canada, Mexico, Asia-Pacific, China, India, Japan, South Korea, Australia, Indonesia, Singapore, Rest of Asia-Pacific, Europe, Germany, France, UK, Italy, Spain, Russia, Rest of Europe, Central & South America, Brazil, Argentina, Rest of South America, Middle East & Africa, Saudi Arabia, Turkey, Rest of Middle East & Africa.

Liraglutide Breakdown by Application: Hospital, Drug Store.

Find more information on this report at https://www.inforgrowth.com/global-liraglutide-market-professional-survey-report-2018.

The study objectives of this report are:
To analyze and study the global Liraglutide capacity, production, value, consumption, status (2013-2017) and forecast (2018-2025);
Focuses on the key Liraglutide manufacturers, to study the capacity, production, value, market share and development plans in future.
Focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis.
To define, describe and forecast the market by type, application and region.
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends and factors driving or inhibiting the market growth.
To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
To strategically analyze each submarket with respect to individual growth trend and their contribution to the market.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

Table of Content:
1. Industry Overview of Liraglutide
2. Manufacturing Cost Structure Analysis of Liraglutide
3. Technical Data and Manufacturing Plants Analysis of Liraglutide
4. Global Liraglutide Overall Market Overview
5. Liraglutide Regional Market Analysis
6. Global 2013-2018E Liraglutide Segment Market Analysis (by Type)
7. Global 2013-2018E Liraglutide Segment Market Analysis (by Application)
8. Major Manufacturers Analysis of Liraglutide
9. Development Trend of Analysis of Liraglutide Market
10. Liraglutide Marketing Type Analysis
11. Consumers Analysis of Liraglutide
12. Conclusion of the Global Liraglutide Market Professional Survey Report 2017.

About InForGrowth:
Reports directory: https://www.inforgrowth.com/search?category=all&query=
Contact for enquiries: https://www.inforgrowth.com/contact
We are a market-intelligence company formed with the objective of providing clients access to the most relevant and accurate research content for their growth needs. At InForGrowth, we understand Research requirements and help a client in taking informed business critical decisions. Given the complexities and interdependencies of market-intelligence, there is always more than one source to explore and arrive at the right answer. Through our smart search feature and our reliable & trusted publishing partners, we are paving way for a more simplified and relevant research.

For all your Research needs, reach out to us at:
Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USA
Email: info@inforgrowth.com
Phone: +1-909-329-2808

This release was published on openPR.